- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 15/16 - Masculine contraceptives
Patent holdings for IPC class A61P 15/16
Total number of patents in this class: 157
10-year publication summary
|
3
|
7
|
6
|
6
|
15
|
14
|
14
|
6
|
10
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bayer Schering Pharma AG | 348 |
5 |
| Kissei Pharmaceutical Co., Ltd. | 176 |
5 |
| Regents of the University of Minnesota | 2765 |
5 |
| Lunella Biotech, Inc. | 102 |
5 |
| Dana-Farber Cancer Institute, Inc. | 2633 |
4 |
| Bayer Pharma AG | 1029 |
3 |
| Memorial Sloan-Kettering Cancer Center | 1999 |
3 |
| St. Jude Children's Research Hospital | 240 |
3 |
| University of Newcastle | 15 |
3 |
| University of Pretoria | 123 |
3 |
| Contraline, Inc. | 27 |
3 |
| Orphagen Pharmaceuticals, Inc. | 7 |
3 |
| Kbio Holdings Limited | 25 |
3 |
| Pharmajor International | 4 |
3 |
| Communitreat Ltd. | 3 |
3 |
| The Regents of the University of California | 20534 |
2 |
| Centre National de La Recherche Scientifique | 10865 |
2 |
| Abbvie Inc. | 1843 |
2 |
| Ayumi Pharmaceutical Corporation | 21 |
2 |
| Baylor College of Medicine | 993 |
2 |
| Other owners | 93 |